Company Filing History:
1 out of 832,912 Years Active: 2018
Title: Sandrine Bezie: Innovator in Transplant Rejection Prevention
Introduction
Sandrine Bezie is a notable inventor based in Nantes, France. She has made significant contributions to the field of immunology, particularly in the area of transplant rejection prevention. Her innovative work has the potential to improve patient outcomes in transplantation and autoimmune diseases.
Latest Patents
Sandrine Bezie holds a patent for a method aimed at inhibiting or reducing transplant rejection through the administration of interleukin-34. This invention relates to an isolated interleukin-34 (IL-34) polypeptide that can be used to prevent or treat graft rejection, autoimmune diseases, unwanted immune responses against therapeutic proteins, and allergies. The patent also outlines an in vitro method for assessing a patient's risk of transplant rejection or autoimmune diseases by determining the expression level of IL-34 in biological samples. The presence of IL-34 indicates a reduced risk of these conditions.
Career Highlights
Throughout her career, Sandrine has focused on advancing medical research and developing innovative solutions to complex health issues. Her work has garnered attention for its potential to transform the way transplant rejection is managed in clinical settings.
Collaborations
Sandrine collaborates with esteemed colleagues in her field, including Carole Guillonneau and Ignacio Anegon. These partnerships enhance her research and contribute to the advancement of immunological studies.
Conclusion
Sandrine Bezie's contributions to the field of immunology, particularly through her patent on interleukin-34, highlight her role as an innovator in transplant rejection prevention. Her work promises to make a significant impact on patient care and treatment strategies in the future.